 Data suggest that undertreatment of rheumatoid arthritis RA patients may be in part due to inadequate decision support when they face whether or not to start biologic therapy. No proven way exists to inform or support RA patients who are candidates for biologic therapy. Communicating information about biologic medication is particularly challenging because of the sheer number of risks to disclose, the difficulty explaining the risks of extremely rare adverse events AEs, and the tendency for people to discount or underweight future benefits. 